Viking Therapeutics (VKTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.42B and a free-cash-flow yield of -9.2%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Lagging · -23.4% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-73.0%
How far the last close sits under the highest price of the past five years.
Market cap
$3.42B
Trailing P/E
—
Price / book
5.8
Price / sales
—
FCF yield
-9.2%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.7
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
VKTX earnings
Next report: Feb 10, 2027 (Q4 2026, EPS estimate -$1.35).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 28, 2026
-$1.55
-$1.07
-44.9%
$0
Q2 2026
Jul 29, 2026
-$1.10
-$1.21
+9.1%
$0
Q1 2026
Apr 29, 2026
-$1.37
-$0.91
-50.5%
$0
Q4 2025
Feb 11, 2026
-$1.38
-$0.90
-53.3%
$0
VKTX analyst price target
Median target $95.00 from 19 analysts, ranging $34.00 – $125.00.
Nama's AI scorecard currently rates Viking Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does VKTX report earnings?
Viking Therapeutics's next scheduled report is on Feb 10, 2027. Analysts expect EPS of -$1.35.
What is the VKTX price target?
The median analyst price target from 19 analysts is $95.00, with a range of $34.00 – $125.00.
Is VKTX Shariah compliant?
Nama's AAOIFI-style screen reads Viking Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.